Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Beam Therapeutics Inc. (BEAM : NSDQ)

• Company Description    Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts. Number of Employees: 511

• Price / Volume Information    Yesterday's Closing Price: $25.10 Daily Weekly Monthly 20 Day Moving Average: 2,547,926 shares Shares Outstanding: 102.88 (millions) Market Capitalization: $2,582.26 (millions) Beta: 2.18 52 Week High: $38.26 52 Week Low: $15.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -26.02% -26.57% 12 Week -17.24% -19.51% Year To Date -9.45% -13.63%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 238 Main Street - Cambridge,MA 02142 USA ph: 857-327-8775 fax: - investors@beamtx.com https://beamtx.com

• General Corporate Information    Officers John Evans - Chief Executive Officer and Director Sravan Emany - Chief Financial Officer Bethany Cavanagh - Senior Vice President; Finance Graham Cooper - Director Mark Fishman - Director Peer Information Beam Therapeutics Inc. (CORR.) Beam Therapeutics Inc. (RSPI) Beam Therapeutics Inc. (CGXP) Beam Therapeutics Inc. (BGEN) Beam Therapeutics Inc. (GTBP) Beam Therapeutics Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 07373V105 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/04/26 Share - Related Items Shares Outstanding: 102.88 Most Recent Split Date: (:1) Beta: 2.18 Market Capitalization: $2,582.26 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.05 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.16 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.21 Price/Cash Flow: - Price / Sales: 15.74 EPS Growth vs. Year Ago Period: 26.61% vs. Previous Quarter: -810.00% Sales Growth vs. Year Ago Period: 324.87% vs. Previous Quarter: -72.19% ROE 06/30/26 - - 03/31/26 - -29.00 12/31/25 - -30.65 ROA 06/30/26 - - 03/31/26 - -22.61 12/31/25 - -23.73 Current Ratio 06/30/26 - - 03/31/26 - 16.99 12/31/25 - 13.09 Quick Ratio 06/30/26 - - 03/31/26 - 16.99 12/31/25 - 13.09 Operating Margin 06/30/26 - - 03/31/26 - -195.22 12/31/25 - -239.82 Net Margin 06/30/26 - - 03/31/26 - -39.66 12/31/25 - -57.24 Pre-Tax Margin 06/30/26 - - 03/31/26 - -40.23 12/31/25 - -57.24 Book Value 06/30/26 - - 03/31/26 - 11.33 12/31/25 - 12.20 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.09 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 7.92 12/31/25 - 0.00

Powered by Zacks Investment Research ©